Lindahl acted as the legal advisor for Senzime AB (publ) when it out-licenses its medical device product OnZurf® Probe to the Italian medical device company MOSS S.pA and for the European market. The OnZurf® Probe is designed to enable continuous sampling from gastro-intestinal organs such as esophagus, stomach, and liver. By monitoring the organ surface, it is possible to detect elevations in lactate and other metabolic markers as early indicators of ischemia and post-operative complications.
As a result of the licensing agreement, Senzime will transfer the legal manufacturing rights and all related product liabilities related to the OnZurf Probe to MOSS, including any future development costs. Senzime will keep rights to commercialize OnZurf Probe on all markets outside of Europe.
MOSS will pay Senzime a fixed license royalty per unit sold on the European market over a period of 10 years. The fixed royalty level corresponds to a double-digit percentage of OnZurf Probe’s estimated sales value. The forecasted royalty income to Senzime during the agreement period amounts to more than SEK 100 million and the first royalty payments are expected to occur in 2022.
Lindahl’s team consisted of av Hugo Norlén, Erika Svensson och Amanda Sjöberg.
For further reading: https://www.senzime.com/cisionpost/?post=83EE4C850A41E505
